Researcher

    Pierre Hardy , Ph.D.

    pierre.hardy@recherche-ste-justine.qc.ca
    Pierre Hardy
    Research Axis
    Fetomaternal and Neonatal Pathologies
    Research Theme
    Fetal development and prematurity
    Address
    CHUSJ - Centre de Recherche

    Phone
    514 345-4931 #3656

    Fax
    514 345-4801

    Title

    • Professor, Department of Pediatrics, University of Montreal.
    • Professor, Department of Pharmacology, University of Montreal.
    • Pediatrician-Neonatologist, CHU Sainte-Justine and CHU Sainte-Justine Research Center.

    Education

    • Postdoctoral Fellow, Institute for Medicine & Engineering, University of Philadelphia, Philadelphia, USA, 2000-2002.
    • PhD in Pharmacology, University of Montreal, 1995-2000.
    • Fellowship in Pediatrics & Neonatology, McGill University, 1985-1994.
    • MD, Université Laval, 1979-1984.

    Research Interests

    Emerging role for cell-derived microparticles in cancer therapy

    One of the major distinguishing features of today’s pharmacology is the drive to produce multiple therapeutic approaches against an illness. For example, against cancer, some will call on inhibitors at different stages of cellular production, while others will try to asphyxiate tumors by impeding blood vessel proliferation. The lymphocyte-derived microparticles (LMP) present themselves to some extent as cellular residues from lymphocytes. LMP present a new line of attack on two fronts against breast cancer. First LMP can fight cellular proliferation and second LMP promise to exert an anti-angiogenic action. One of the problems of chemotherapy is the enormous secondary effects it causes in patients because it also attacks non-cancerous cells. This is where LMPs could make a big contribution. They don’t kill cancerous cells, but they could halt their proliferation. That means that chemotherapy, from one treatment to another, could be shortened and prove much less taxing for patients because LMPs could have blocked the increase of cancerous cells between treatments. The industrial production of LMPs is relatively easy and their manufacturing cost low. A different route to mass production is also possible through personalized therapies, one of the more exciting potentials of these particles. They open the door to treatments tailor-made for each patient. We could take blood from the patient, extract the lymphocytes and, after having cultivated and treated them to obtain microparticles, reinject them into the patient. The risk of rejection and of many secondary effects would thus be reduced.

    Effects of lymphocyte-derived microparticles in angiogenesis

    Our current findings provide evidence for the first time, that lymphocyte-derived microparticles (LMPs) inhibit vascular angiogenesis by affecting both proliferation and migration of endothelial cells, without increasing apoptosis and necrosis. Our results also suggest that LMPs may act through oxidative stress and VEGF signaling pathways to modulate angiogenesis. The central role of VEGF in angiogenesis makes it attractive as a therapeutic target for anti-angiogenic drugs. Understanding how LMPs interrupt VEGF signaling will provide therapeutic strategies aimed at reducing the abnormalities of neovascularization in different pathological processes.

    Role of CD36 (scavenger receptor) in corneal neovascularization

    Our work provide the first demonstration of the protective involvement of CD36 in limiting inflammatory CNV. Other anti-angiogenic factors such as endostatin, thrombospondin, PEDF, and maspin have also been found in the uninjured cornea, reaffirming the importance of these types of factors in maintaining transparency of the healthy cornea. Our observations have significant implications for the treatment of ocular neovascularization in that CD36 stimulants would be effective not only in patients with ongoing CNV, but also in those presenting established CNV. Findings may not only apply to corneal inflammation following injury or infection, but may also be relevant in corneal graft failure which involves an inflammatory immune rejection.

    Awards and Distinctions

    • Research Grant, Research on age-related macular degeneration, FRQS, 2015-2016
    • Junior 1 Research Scholar, Fonds de la recherche en santé du Québec, 2002-2006.
    • Postdoctoral Fellowship, Canadian Institutes of Health Research, 1999-2002.
About this page
Edited by Hoffmann Maude

Created on 9/18/2014
Alert or send a suggestion

Every dollar counts!

Thank you for your generosity.

It's people like you that allow us to accelerate research and heal more children better every year and, as such, offer among the best healthcare in the world.

It's also possible to give by mail or by calling toll-free

1-888-235-DONS (3667)

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine